Exploring Predictors of Symptoms Relapse After Discontinuation of Successful 3-Month of Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Trial.

Trial Profile

Exploring Predictors of Symptoms Relapse After Discontinuation of Successful 3-Month of Treatment With a Tolterodine Prolonged Release Capsules (4 mg, Once Daily) in Overactive Bladder Patients: A Prospective Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2011

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Apr 2011 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
    • 21 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2009 Planned end date changed from Dec 2008 to Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top